Literature DB >> 12704448

Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

József Tímár1, Andrea Ladányi, István Peták, András Jeney, László Kopper.   

Abstract

Therapy of tumor progression and the metastatic disease is the biggest challenge of clinical oncology. Discovery of the diverse molecular pathways behind this complex disease outlined an approach to better treatment strategies. The development of combined cytotoxic treatment protocols has produced promising results but no breakthrough in the clinical management of metastatic disease. The multiple - specific and non-specific pathways and cellular targets of tumor progression are outlined in this review. Such an approach, individually designed for various cancer types, may have a better chance to treat or even cure cancer patients with progressive disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12704448     DOI: 10.1007/BF03033715

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  212 in total

Review 1.  The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.

Authors:  R E Favoni; A de Cupis
Journal:  Pharmacol Rev       Date:  2000-06       Impact factor: 25.468

2.  Src family kinase inhibitor PP2 restores the E-cadherin/catenin cell adhesion system in human cancer cells and reduces cancer metastasis.

Authors:  Jeong-Seok Nam; Yoshinori Ino; Michiie Sakamoto; Setsuo Hirohashi
Journal:  Clin Cancer Res       Date:  2002-07       Impact factor: 12.531

3.  Inhibition of melanoma cells tumorigenicity by the snake venom toxin jararhagin.

Authors:  Mário César Corrêa; Durvanei A Maria; Ana M Moura-da-Silva; Kazumi F Pizzocaro; Itamar R G Ruiz
Journal:  Toxicon       Date:  2002-06       Impact factor: 3.033

Review 4.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

5.  p53 dependence of Fas induction and acute apoptosis in response to 5-fluorouracil-leucovorin in human colon carcinoma cell lines.

Authors:  I Petak; D M Tillman; J A Houghton
Journal:  Clin Cancer Res       Date:  2000-11       Impact factor: 12.531

6.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3.

Authors:  J C Gutheil; T N Campbell; P R Pierce; J D Watkins; W D Huse; D J Bodkin; D A Cheresh
Journal:  Clin Cancer Res       Date:  2000-08       Impact factor: 12.531

Review 7.  IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.

Authors:  Roy S Herbst; Waun Ki Hong
Journal:  Semin Oncol       Date:  2002-10       Impact factor: 4.929

8.  Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions.

Authors:  D Lawrence; Z Shahrokh; S Marsters; K Achilles; D Shih; B Mounho; K Hillan; K Totpal; L DeForge; P Schow; J Hooley; S Sherwood; R Pai; S Leung; L Khan; B Gliniak; J Bussiere; C A Smith; S S Strom; S Kelley; J A Fox; D Thomas; A Ashkenazi
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

9.  In vivo characterization of combination antitumor chemotherapy with calcium channel blockers and cis-diamminedichloroplatinum(II).

Authors:  J M Onoda; K K Nelson; J D Taylor; K V Honn
Journal:  Cancer Res       Date:  1989-06-01       Impact factor: 12.701

Review 10.  Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer.

Authors:  József Tímár; Károly Lapis; József Dudás; Anna Sebestyén; László Kopper; Ilona Kovalszky
Journal:  Semin Cancer Biol       Date:  2002-06       Impact factor: 15.707

View more
  1 in total

1.  Different cDNA microarray patterns of gene expression reflecting changes during metastatic progression in adenoid cystic carcinoma.

Authors:  Dan Huang; Wantao Chen; Ronggen He; Fan Yu; Zhiyuan Zhang; Weiliu Qiu
Journal:  World J Surg Oncol       Date:  2003-12-19       Impact factor: 2.754

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.